Trial Profile
Phase II, Multicenter, Randomized, Double-blind, Intraindividually Placebo Controlled Clinical Trial, to Evaluate Efficacy and Safety of p144 Topical Administration for Skin Fibrosis in Patients With Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2019
Price :
$35
*
At a glance
- Drugs Disitertide (Primary)
- Indications Systemic scleroderma
- Focus Proof of concept; Therapeutic Use
- Sponsors Isdin
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 13 May 2014 New trial record